Leta i den här bloggen


torsdag 22 mars 2018

TRIM62 (Kr.1p35.19 DEAR1 (Ductal Epithelium Associated RING chromosome 1)


TRIM 62 ( Kr.1p35.1) DEAR1, FLJ10759




PubMed GENE https://www.ncbi.nlm.nih.gov/gene/55223
Also known as DEAR1 (Ductal Epithelium Associated RING chromosome 1
Expression Ubiquitous expression in skin (RPKM 2.0), brain (RPKM 1.3) and 25 other tissues See more Orthologs mouse all

Rakenne. Konservoidut domeenit.

Conserved domains (4) summary
smart00336
Location:88 → 125
BBOX; B-Box-type zinc finger
cd13744
Location:284 → 471
SPRY_PRY_TRIM62; PRY/SPRY domain in tripartite motif-binding protein 62 (TRIM62)
cl17238
Location:11 → 53
RING; RING-finger (Really Interesting New Gene) domain, a specialized type of Zn-finger of 40 to 60 residues that binds two atoms of zinc; defined by the 'cross-brace' motif C-X2-C-X(9-39)-C-X(1-3)- H-X(2-3)-(N/C/H)-X2-C-X(4-48)C-X2-C; probably involved in ...
cl23765
Location:136 → 255
iSH2_PI3K_IA_R; Inter-Src homology 2 (iSH2) helical domain of Class IA Phosphoinositide 3-kinase Regulatory subunits

Isoformi 1 historia ja rakenne:

E3 ubiquitin-protein ligase TRIM62 isoform 1 [Homo sapiens]

NCBI Reference Sequence: NP_060677.2 Identical Proteins FASTA Graphics
LOCUS       NP_060677                475 aa            linear   PRI 14-MAR-2018
DEFINITION  E3 ubiquitin-protein ligase TRIM62 isoform 1 [Homo sapiens].
ACCESSION   NP_060677
VERSION     NP_060677.2
DBSOURCE    REFSEQ: accession NM_018207.2
KEYWORDS    RefSeq.
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
            Catarrhini; Hominidae; Homo.
REFERENCE   1  (residues 1 to 475)
  AUTHORS   Liu TY, Chen J, Shang CL, Shen HW, Huang JM, Liang YC, Wang W, Zhao
            YH, Liu D, Shu M, Guo LY, Hu Z and Yao SZ.
  TITLE     Tripartite motif containing 62 is a novel prognostic marker and
            suppresses tumor metastasis via c-Jun/Slug signaling-mediated
            epithelial-mesenchymal transition in cervical cancer
  JOURNAL   J. Exp. Clin. Cancer Res. 35 (1), 170 (2016)
   PUBMED   27793172
  REMARK    GeneRIF: Results found that TRIM62 was frequently down-regulated in
            both human cervical cancer (CC) cells and tissues. Low expression
            of TRIM62 in CC tissues was associated with aggressive
            clinicopathological features of CC patients. Its overexpression
            inhibits proliferation, migration and invasion of cervical cancer
            cells.
            Publication Status: Online-Only
REFERENCE   2  (residues 1 to 475)
  AUTHORS   Cao Z, Conway KL, Heath RJ, Rush JS, Leshchiner ES, Ramirez-Ortiz
            ZG, Nedelsky NB, Huang H, Ng A, Gardet A, Cheng SC, Shamji AF,
            Rioux JD, Wijmenga C, Netea MG, Means TK, Daly MJ and Xavier RJ.
  TITLE     Ubiquitin Ligase TRIM62 Regulates CARD9-Mediated Anti-fungal
            Immunity and Intestinal Inflammation
  JOURNAL   Immunity 43 (4), 715-726 (2015)
   PUBMED   26488816
  REMARK    GeneRIF: TRIM62 is a CARD9-binding partner. TRIM62 facilitated
            K27-linked poly-ubiquitination of CARD9.
REFERENCE   3  (residues 1 to 475)
  AUTHORS   Quintas-Cardama A, Zhang N, Qiu YH, Post S, Creighton CJ, Cortes J,
            Coombes KR and Kornblau SM.
  TITLE     Loss of TRIM62 expression is an independent adverse prognostic
            factor in acute myeloid leukemia
  JOURNAL   Clin Lymphoma Myeloma Leuk 15 (2), 115-127 (2015)
   PUBMED   25248926
  REMARK    GeneRIF: Low TRIM62 levels, consistent with a tumor suppressor
            role, represent an independent adverse prognostic factor in AML.
REFERENCE   4  (residues 1 to 475)
  AUTHORS   Chen N, Balasenthil S, Reuther J and Killary AM.
  TITLE     DEAR1, a novel tumor suppressor that regulates cell polarity and
            epithelial plasticity
  JOURNAL   Cancer Res. 74 (20), 5683-5689 (2014)
   PUBMED   25261235
  REMARK    GeneRIF: DEAR1 is important in the regulation of the breast tumor
            microenvironment, polarity, and epithelial-mesenchymal transition.
            [Review]
            Review article
REFERENCE   5  (residues 1 to 475)
  AUTHORS   Chen N, Balasenthil S, Reuther J, Frayna A, Wang Y, Chandler DS,
            Abruzzo LV, Rashid A, Rodriguez J, Lozano G, Cao Y, Lokken E, Chen
            J, Frazier ML, Sahin AA, Wistuba II, Sen S, Lott ST and Killary AM.
  TITLE     DEAR1 is a chromosome 1p35 tumor suppressor and master regulator of
            TGF-beta-driven epithelial-mesenchymal transition
  JOURNAL   Cancer Discov 3 (10), 1172-1189 (2013)
   PUBMED   23838884
  REMARK    GeneRIF: results provide compelling evidence that DEAR1 is a
            critical tumor suppressor involved in multiple human cancers and
            provide a novel paradigm for regulation of TGF-beta-induced EMT
            through DEAR1's regulation of SMAD3 protein levels
REFERENCE   6  (residues 1 to 475)
  AUTHORS   Uchil PD, Hinz A, Siegel S, Coenen-Stass A, Pertel T, Luban J and
            Mothes W.
  TITLE     TRIM protein-mediated regulation of inflammatory and innate immune
            signaling and its association with antiretroviral activity
  JOURNAL   J. Virol. 87 (1), 257-272 (2013)
   PUBMED   23077300
REFERENCE   7  (residues 1 to 475)
  AUTHORS   Lott ST, Chen N, Chandler DS, Yang Q, Wang L, Rodriguez M, Xie H,
            Balasenthil S, Buchholz TA, Sahin AA, Chaung K, Zhang B, Olufemi
            SE, Chen J, Adams H, Band V, El-Naggar AK, Frazier ML, Keyomarsi K,
            Hunt KK, Sen S, Haffty B, Hewitt SM, Krahe R and Killary AM.
  TITLE     DEAR1 is a dominant regulator of acinar morphogenesis and an
            independent predictor of local recurrence-free survival in
            early-onset breast cancer
  JOURNAL   PLoS Med. 6 (5), e1000068 (2009)
   PUBMED   19536326
  REMARK    GeneRIF: The evidence for the genetic alteration and loss of
            expression of DEAR1 in breast cancer and for the functional role of
            DEAR1 in the dominant regulation of acinar morphogenesis in 3D
            culture
REFERENCE   8  (residues 1 to 475)
  AUTHORS   Muthuswamy SK.
  TITLE     A new tumor suppressor that regulates tissue architecture
  JOURNAL   PLoS Med. 6 (5), e1000073 (2009)
   PUBMED   19536324
  REMARK    GeneRIF: DEAR1 is a predictive biomarker for early onset breast
            cancer.
REFERENCE   9  (residues 1 to 475)
  AUTHORS   Uchil PD, Quinlan BD, Chan WT, Luna JM and Mothes W.
  TITLE     TRIM E3 ligases interfere with early and late stages of the
            retroviral life cycle
  JOURNAL   PLoS Pathog. 4 (2), e16 (2008)
   PUBMED   18248090
REFERENCE   10 (residues 1 to 475)
  AUTHORS   Colland F, Jacq X, Trouplin V, Mougin C, Groizeleau C, Hamburger A,
            Meil A, Wojcik J, Legrain P and Gauthier JM.
  TITLE     Functional proteomics mapping of a human signaling pathway
  JOURNAL   Genome Res. 14 (7), 1324-1332 (2004)
   PUBMED   15231748
COMMENT     VALIDATED REFSEQ: This record has undergone validation or
            preliminary review. The reference sequence was derived from
            DA338982.1, BM722392.1, BC007999.1, AK001621.1 and CX872720.1.
            On Dec 10, 2008 this sequence version replaced NP_060677.1.
            
            Transcript Variant: This variant (1) represents the longer
            transcript and encodes the longer isoform (1).
            
            Publication Note:  This RefSeq record includes a subset of the
            publications that are available for this gene. Please see the Gene
            record to access additional publications.
            
            ##Evidence-Data-START##
            Transcript exon combination :: BC001222.1, AK001621.1 [ECO:0000332]
            RNAseq introns              :: mixed/partial sample support
                                           SAMEA1965299, SAMEA1966682
                                           [ECO:0000350]
            ##Evidence-Data-END##
FEATURES             Location/Qualifiers
     source          1..475
                     /organism="Homo sapiens"
                     /db_xref="taxon:9606"
                     /chromosome="1"
                     /map="1p35.1"
     Protein         1..475
                     /product="E3 ubiquitin-protein ligase TRIM62 isoform 1"
                     /EC_number="2.3.2.27"
                     /note="ductal epithelium-associated RING Chromosome 1;
                     tripartite motif-containing protein 62; E3
                     ubiquitin-protein ligase TRIM62; RING-type E3 ubiquitin
                     transferase TRIM62"
                     /calculated_mol_wt=54137
     Region          11..53
                     /region_name="RING"
                     /note="RING-finger (Really Interesting New Gene) domain, a
                     specialized type of Zn-finger of 40 to 60 residues that
                     binds two atoms of zinc; defined by the 'cross-brace'
                     motif C-X2-C-X(9-39)-C-X(1-3)-
                     H-X(2-3)-(N/C/H)-X2-C-X(4-48)C-X2-C; probably involved
                     in...; cl17238"
                     /db_xref="CDD:302633"
     Site            order(11,14,26,28,31,34,50,53)
                     /site_type="other"
                     /note="cross-brace motif"
                     /db_xref="CDD:238093"
     Region          88..125
                     /region_name="BBOX"
                     /note="B-Box-type zinc finger; smart00336"
                     /db_xref="CDD:197662"
     Site            order(93,96,114,120)
                     /site_type="other"
                     /note="Zn2+ binding site [ion binding]"
                     /db_xref="CDD:237988"
     Region          136..255
                     /region_name="iSH2_PI3K_IA_R"
                     /note="Inter-Src homology 2 (iSH2) helical domain of Class
                     IA Phosphoinositide 3-kinase Regulatory subunits; cl23765"
                     /db_xref="CDD:304922"
     Region          284..471
                     /region_name="SPRY_PRY_TRIM62"
                     /note="PRY/SPRY domain in tripartite motif-binding protein
                     62 (TRIM62); cd13744"
                     /db_xref="CDD:293978"
     CDS             1..475
                     /gene="TRIM62"
                     /gene_synonym="DEAR1"
                     /coded_by="NM_018207.2:639..2066"
                     /note="isoform 1 is encoded by transcript variant 1"
                     /db_xref="CCDS:CCDS376.1"
                     /db_xref="GeneID:55223"
                     /db_xref="HGNC:HGNC:25574"
                     /db_xref="MIM:616755"
ORIGIN      
        1 macslkdell csiclsiyqd pvslgcehyf crrcitehwv rqeaqgardc pecrrtfaep
       61 alapslklan iveryssfpl dailnarraa rpcqahdkvk lfcltdrall cffcdepalh
      121 eqhqvtgidd afdelqrelk dqlqalqdse rehtealqll krqlaetkss tkslrttige
      181 aferlhrllr erqkamleel eadtartltd ieqkvqrysq qlrkvqegaq ilqerlaetd
      241 rhtflagvas lserlkgkih etnltyedfp tskytgplqy tiwkslfqdi hpvpaaltld
      301 pgtahqrlil sddctivayg nlhpqplqds pkrfdvevsv lgseafssgv hywevvvaek
      361 tqwviglahe aasrkgsiqi qpsrgfyciv mhdgnqysac tepwtrlnvr dkldkvgvfl
      421 dydqgllify naddmswlyt frekfpgklc syfspgqsha ngknvqplri ntvri
//
Artikkeleita Related articles in PubMed

TRIM62 ja EMT( epiteliaalismesenkymaalinen siirtymä): c-Jun/Slug

  • Suomennosta: TRIM 62 näyttää olevan usein alassäätyneenä  sekä cervixsyöpäsoluissa ja -kudoksissa. TRIM62 geenin matala ilmentymä assosioitui  aggressiiviseen kliinispatologiseen kulkuun.  Myös kirurgisesti hoidetun CC syövän   yleisenä ja  taudittoman aikavälin  riippumattomana  huonon prognoosin merkkinä oli TRIM62:n matala esiintymä.  TRIM62:n vahvistettu ilmentymä CC-soluissa  esti merkitsevästi  syöpäsolujen kykyä proliferoitua, migroitua ja invasoitua in vitro.TRIM62 kykenee estämään EMT:n inhiboimalla c-Jun/Slug signaloinnin. TRIM62:n estävä vaikutus tuumorin proliferaatioon  saattaisi johtua solusyklin proteiinien SykliiniD1 ja p27  säätelystä c-Jun- tekijään kohdistumisen kautta.. Johtopäätös: TRIM62 on mahdollinen prognostinen biomerkitsijä CC:ssä ja se tukahduttaa  CC-metastasointia estämällä c-Jun/Slug  signaloinnin välittämän  EMT:n, epiteliaalisen-mesenkymaalisen transition.

TRIM62 ja TGF-beta/SMAD3/SNAIL1/2 välitteinen EMT

  • DEAR1, a novel tumor suppressor that regulates cell polarity and epithelial plasticity. Chen N, et al. Cancer Res, 2014 Oct 15. PMID 25261235, Free PMC Article This review will highlight the role of the novel TRIM protein DEAR1 (annotated as TRIM62) in the regulation of apical-basal polarity and acinar morphogenesis as well as its function as a chromosome 1p35 tumor suppressor and negative regulator of TGFβ-driven epithelial-mesenchymal transition (EMT). DEAR1 binds to and promotes the ubiquitination of SMAD3, the major effector of TGFβ-mediated EMT, as well as downregulates SMAD3 targets SNAIL1/2, master transcriptional regulators of EMT. Cumulative results suggest a novel paradigm for DEAR1 in the regulation of the breast tumor microenvironment, polarity, and EMT. Because DEAR1 undergoes loss-of-function mutations, homozygous deletion, as well as copy-number losses in multiple epithelial cancers, including breast cancer, DEAR1 has clinical use as a predictive and prognostic biomarker as well as for stratifying breast cancers and potentially other epithelial tumor types for targeted therapies aimed at the pathways regulated by DEAR1.
  • Suomennosta: TRIM62 säätelee solun apikaalisbasaalista polariteettia ja akinaarista morfogeneesiä, toimii tuumorisuppressorina ja TGFbeta-välitteisen EMT:n negatiivisena säätelijänä. TRIM62 sitoutuu SMAD3-tekijään ja ubikitinoi sen; säätää alas SMAD3 kohteen SNAIL1/2 , joka säätelee epiteliaalismesenkymaalista transitiota (EMT). TRIM62 tekee mutaatioita, homozygootteja deleetioita, kopioluvun katoa useissa epiteliaalisissa syövissä kuten rintasyövässä, joissa se menettää funktioita. Kliinisenä markkerina sitä voi käyttää, kun suunnitellaan kodhennettuja hoitoja TRIM62-säätelyteihin.

TRIM62 menetys ja vaikutus leukemiakantasolun homeostaasiin

  • Loss of TRIM62 expression is an independent adverse prognostic factor in acute myeloid leukemia. Quintás-Cardama A, et al. Clin Lymphoma Myeloma Leuk, 2015 Feb. PMID 25248926, Free PMC Article TRIM62 loss was associated with altered expression of proteins involved in leukemia stem cell homeostasis (β-catenin and Notch), cell motility, and adhesion (integrin-β3, ras-related C3 botulinum toxin substrate [RAC], and fibronectin), hypoxia (Hypoxia-inducible factor 1-alpha [HIF1α], egl-9 family hypoxia-inducible factor 1 [Egln1], and glucose-regulated protein, 78 kDa [GRP78]), and apoptosis (B-cell lymphoma-extra large (BclXL) and caspase 9).
  • Suomennosta: TRIM62 menetys liittyy monen proteiinin muuntuneeseen ilmentymiseen.Tällaisia proteiineja ovat: leukemiakantasolun homeostaasiin osallistuvat proteiinit (betakateniini ja Notch), solumotiliteettiproteiinit, adheesioproteiinit (integriini-beta3, RAC ja fibronektiini) , hypoksiaan liittyvät proteiinit (HIF1alfa, Egln1 ja GRP78 glukoosin säätelemä proteiini 78kDa) ja apoptoosiin liittyvät proteiinit (BcLXL ja kaspaasi9) .

TRIM62 tuumorisuppressori, joka sääetlee kudosarkkitehtuuria


    Suomennosta: TRIM62 sitoutuu CARD9 proteiiniin, joka on sentraalinen komponentti antifungaalisessa luonnollisessa immuunivasteessa C-tyypisen lektiinireseptorien kautta tapahtuvassa signaloinnissa. TRIM62 nopeuttaa CARD9 K27-linkkiytynyttä ubikitinaatiota. CARD9:ssä havaittiin K125 ubikitinaatio, mikä on essentielli CARD9-aktiivisuudelle. Card9-vajaat hiiret olivat alttiita sienitulehduksille. Myös Trim62 vajeiset hiiret omasivat lisääntyneen alttiuden sienitulehduksille.
  • Suomennosta: TRIM62 assosioituneena E2 entsyymiin UBE2D2 katalysoi autoubikitinaatiotansa, mikä vaati intaktin RING finger domaanin ja johti TRIM62:n proteosomaaliseen hajoamiseen. TRIM62 on sytoplasminen proteiini.
  • E2 ubikitiiniligaasi joka avustaa TRIM62:n autoubikitinaatiota ja täten hajoamista mikä säätelee sen määrää. (UBE2D2 , UbcH5b kr. 5q31.2) Mm. HIV-1 integraasi tekee interaktion UBE2D2 entsyymiin, mikä on virukselle suotuisa. https://www.ncbi.nlm.nih.gov/gene/7322



PÄIVITYS 7.5. 2018

Inga kommentarer:

Skicka en kommentar